SCHEMBL20907239

SCHEMBL20907239

Nc1ccc(CN2CCC(CNC3CC3)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
ACHE P22303 6/20 0.51
BACE1 P56817 6/20 0.51
BCHE P06276 4/20 0.51
SIGMAR1 Q99720 1/20 0.51
KDM1A O60341 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAOB P27338 2/20 0.49
CXCR4 P61073 1/20 0.49
LMNA P02545 1/20 0.49
CXCR3 P49682 2/20 0.47
DRD2 P14416 1/20 0.44
HTR2A P28223 1/20 0.44
SLC6A4 P31645 1/20 0.44
SCN5A Q14524 1/20 0.44
DPP7 Q9UHL4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21101096 0.85 BCHE (0.62) ACHEBACE1BCHESIGMAR1CXCR3
SCHEMBL28169202 0.84 CXCR4 (0.68) ALDH1A1ACHEBACE1BCHESIGMAR1
SCHEMBL21101241 0.82 ACHE (0.48) ACHEBACE1BCHEKDM1AMEN1
SCHEMBL21101233 0.82 SIGMAR1 (0.50) ACHEBACE1BCHESIGMAR1KDM1A
SCHEMBL21101338 0.81 CXCR4 (0.49) ACHEBACE1BCHEKDM1AMEN1
SCHEMBL21100972 0.81 CXCR4 (0.49) ACHEBACE1BCHESIGMAR1KDM1A
SCHEMBL21101256 0.80 SIGMAR1 (0.52) ACHEBACE1SIGMAR1KDM1AMAOB
SCHEMBL19725557 0.80 KDM1A (0.67) KDM1AMEN1KMT2AMAOBCXCR4
SCHEMBL21100976 0.79 KDM1A (0.44) ACHEBACE1BCHEKDM1AMEN1
SCHEMBL3311538 0.79 ACHE (0.68) ACHEBACE1BCHESIGMAR1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2688568-B1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2019-06-19 EP disclosed
WO-2019075327-A1 TREATING MERKEL CELL CARCINOMA DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-04-18 WO disclosed